ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPD - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39467609/
These findings suggest the potential clinical relevance of CIIS and P pulmonale as risk indicators for adverse cardiopulmonary events in COPD.
Higher CIIS (≥20) and P pulmonale predict increased risk of mortality and adverse cardiopulmonary events in COPD. Fluticasone furoate/umeclidinium/vilanterol may reduce mortality and cardiovascular events in high-risk patients (CIIS ≥20).
Systematic Review and Meta-Analysis of the Application of T-PEP in the Therapeutic Management of COPD Patients - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39860328/
Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, characterized by chronic mucus hypersecretion (CMH) that exacerbates airway obstruction and accelerates disease progression. Effective...
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, characterized by chronic mucus hypersecretion (CMH) that exacerbates airway obstruction and accelerates disease progression. Effective airway clearance techniques are essential to improve respiratory function and reduce exacerbations.
Safety and efficacy of ensifentrine in COPD: A systemic review and meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39557208/
Ensifentrine significantly enhances lung function, reduces dyspnea, and improves quality of life in COPD patients, especially at a 3 mg dose. These benefits, coupled with a stable safety profile, support...
Ensifentrine improves lung function, dyspnea, and quality of life in COPD patients, particularly at 3 mg, with a stable safety profile, supporting its role as an adjunctive therapy in COPD management.
GOLD Science Committee recommendations for the use of pre- and post-bronchodilator spirometry for the diagnosis of COPD - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39638416/
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) report states that the diagnosis of COPD should be considered in individuals with chronic respiratory symptoms and/or exposure to risk factors....
GOLD 2025 recommends pre-BD spirometry to rule out COPD and post-BD spirometry to confirm, ensuring accurate diagnosis, reducing overdiagnosis, and identifying volume responders while minimizing clinical workload.
The Responsiveness of Exercise Tests in COPD: A Randomized Controlled Trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39173827/
International Standard Randomised Controlled Trial Number (ISRCTN): No. 64759523; URL: https://www.isrctn.com/ISRCTN64759523.
The ESWT and CWRCT showed the highest responsiveness to pulmonary rehabilitation and bronchodilator therapy in COPD patients, with greater improvements observed after rehabilitation compared to bronchodilator therapy.